Cryopreservation of apoptotic cancer cells for use in immunotherapy against cancer
Inventors
Fucikova, Jitka • Koci, Lenka • Pokorna, Katerina • Truxova, Iva • Moserova, Irena • Rozkova, Daniela • Spisek, Radek
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-9562219-B2
Publication Date
2017-02-07
Expiration Date
Abstract
Described herein is a reliable method for preparing a potent vaccine useful for immunotherapy comprising the step of cryopreserving a population of cells undergoing immunogenic cell death, and using such cells to activate dendritic cells for use in immunotherapy. In a specific embodiment, the method comprises cryopreserving cancer cells undergoing cell death, which can be used to prepare a pharmaceutical composition for immunotherapy against cancer.
Core Innovation
The invention relates to methods for preparing a pharmaceutical composition for use in immunotherapy by inducing immunogenic cell death in a population of cancer cells. The cancer cells undergoing immunogenic cell death are cryopreserved in a cryopreservant and subsequently thawed, and the resulting pharmaceutical composition comprises the thawed cancer cells for use in immunotherapy.
A key aspect is that the thawed cancer cells retain one or more hallmarks of immunogenic cell death. The method includes a defined timing relationship between induction of immunogenic cell death and cryopreservation, and the cells are cryopreserved within a time window after induction. The hallmarks are preserved through cryopreservation and thawing.
The document further describes hallmarks such as calreticulin, HSP70, and HSP90, and describes examples of immunogenic cell death induction modalities, including high hydrostatic pressure. The document also describes example contexts where the prepared thawed cells are used as part of immunotherapy-related pharmaceutical compositions.
Claims Coverage
The independent claims are directed to a method for preparing a pharmaceutical composition for immunotherapy using cryopreserved immunogenic cell death cancer cells, with retention of one or more immunogenic cell death hallmarks. The main inventive features are consistent across three claims, with differences in cryopreservation timing after induction and an added reculture timing window in one claim.
Inducing immunogenic cell death in cancer cells; cryopreserving within 2.5 hours; thawing; retaining immunogenic cell death hallmarks
A method comprising inducing immunogenic cell death in a population of cancer cells; cryopreserving the cancer cells undergoing immunogenic cell death in a cryopreservant, wherein the cells are cryopreserved within 2.5 hours after induction of immunogenic cell death; thawing the cryopreserved cancer cells; and preparing a pharmaceutical composition comprising the thawed cancer cells for use in immunotherapy, wherein the thawed cancer cells retain one or more hallmarks of immunogenic cell death.
Inducing immunogenic cell death in cancer cells; cryopreserving within six hours; thawing; retaining immunogenic cell death hallmarks
A method comprising inducing immunogenic cell death in a population of cancer cells; cryopreserving the cancer cells undergoing immunogenic cell death in a cryopreservant, wherein the cells are cryopreserved within six hours after induction of immunogenic cell death; thawing the cryopreserved cancer cells; and preparing a pharmaceutical composition comprising the thawed cancer cells for use in immunotherapy, wherein the thawed cancer cells retain one or more hallmarks of immunogenic cell death.
Inducing immunogenic cell death in cancer cells; thawing with reculture timing before use; retaining immunogenic cell death hallmarks
A method comprising inducing immunogenic cell death in a population of cancer cells; cryopreserving the cancer cells undergoing immunogenic cell death in a cryopreservant; thawing the cryopreserved cancer cells, wherein the thawed cells are put back into culture for at least 1 hour and not more than 6 hours before being used for the pharmaceutical preparation; and preparing a pharmaceutical composition comprising the thawed cancer cells for use in immunotherapy, wherein the thawed cancer cells retain one or more hallmarks of immunogenic cell death.
Coverage centers on preparing an immunotherapy pharmaceutical composition from cryopreserved cancer cells that underwent immunogenic cell death, where the thawed cells retain one or more immunogenic cell death hallmarks. The claims differ by the timing window for cryopreservation after induction and by an additional reculture timing window after thawing in one independent claim.
Stated Advantages
Not explicitly described in patent.
Documented Applications
Not explicitly described in patent.
Interested in licensing this patent?